Swedish Orphan Biovitrum AB (publ)

Research activity in haemophilia A centres on long-term prophylactic management, prevention of joint bleeds, and control of breakthrough bleeding in people with severe disease. The trials also examine treatment continuity in previously treated patients and comparative pharmacokinetics of extended half-life factor VIII products.

• Prophylactic factor VIII therapy
• Joint bleed prevention
• Bleeding episode management
• Pharmacokinetic assessment

Clinical interest extends to sustained treatment use across multiple countries and real-world settings, with a focus on maintaining protection against bleeding complications.